Clarisond, Inc. is a start-up company based in Salem, NH that is commercializing technology to enhance the clarity of medical ultrasound images. Specifically, Clarisond’s technologies address the need for alternative imaging modalities in the area of breast cancer screening. Clarisond currently has a Phase II SBIR grant from the National Science Foundation to develop and commercialize its imaging technology. Clarisond recognizes the need for alternative imaging modalities in women with mammographically dense breast tissue. Ultrasound imaging has been shown to be sensitive to the detection of suspect lesions in such women, but it currently suffers from a high false positive rate. Accordingly, we have positioned our technology to focus on enhancing the quality of breast ultrasound imaging. The Clarisond difference is expected to improve not only the sensitivity to early stage lesions, but also the specificity needed to classify detected features - ultimately reducing false positives. While breast imaging is the initial focus of our technology, it is broadly applicable to general ultrasound imaging.